The adverse effects of recombinant human erythropoietin therapy.
Wong
K C
KC
Department of Medicine, Chinese University of Hong Kong, Shatin.
Li
P K
PK
Lui
S F
SF
Nicholls
M G
MG
Lai
K N
KN
D000740:Anemia / Q000150:complications / Q000628:therapy; D000747:Anemia, Hypochromic / Q000139:chemically induced; D000818:Animals; D004342:Drug Hypersensitivity; D004921:Erythropoietin / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D006947:Hyperkalemia / Q000139:chemically induced*; D006973:Hypertension / Q000139:chemically induced*; D010531:Peritoneal Dialysis, Continuous Ambulatory; D010710:Phosphates / Q000097:blood; D011994:Recombinant Proteins / Q000009:adverse effects; D006435:Renal Dialysis; D012640:Seizures / Q000139:chemically induced*; D013927:Thrombosis / Q000139:chemically induced*; D014511:Uremia / Q000150:complications
D010710:Phosphates; D011994:Recombinant Proteins; D004921:Erythropoietin